Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Ocana

Showing results (1-10 of 97) with videos related to

Pageof 10
Sort By:
Current Cancer Drug Targets|December 10, 2015
Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug DevelopmentAlberto Ocana, Atanasio Pandiella
Cancer Treatment Reviews|October 4, 2016
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategySaroj Niraula, Alberto Ocana
Oncotarget|January 22, 2017
Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studiesAlberto Ocana, Atanasio Pandiella
Journal of the National Cancer Institute|December 7, 2010
When are "positive" clinical trials in oncology truly positive?Alberto Ocana, Ian F Tannock
Breast (Edinburgh, Scotland)|June 27, 2015
One step forward, two steps back: The story of everolimus in advanced breast cancerSaroj Niraula, Alberto Ocana, Eitan Amir
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2011
Clinical research: show us the dataAlberto Ocana, Eitan Amir, Bostjan Seruga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Multidimensional challenges in clinical drug development, regulatory approval, and marketingAlberto Ocana, Bostjan Seruga, Eitan Amir
Lancet (London, England)|February 24, 2015
Pathological complete response in breast cancerAlberto Ocana, Bostjan Seruga, Eitan Amir
Cancer Research|May 20, 2016
Toward Value-Based Pricing to Boost Cancer Research and InnovationAlberto Ocana, Eitan Amir, Ian F Tannock
Nature Reviews. Clinical Oncology|September 23, 2010
Drug resistance in metastatic castration-resistant prostate cancerBostjan Seruga, Alberto Ocana, Ian F Tannock
Pageof 10

Showing results (1-10 of 97) with videos related to

Sort By:
Pageof 10
Current Cancer Drug Targets|December 10, 2015
Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug DevelopmentAlberto Ocana, Atanasio Pandiella
Cancer Treatment Reviews|October 4, 2016
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategySaroj Niraula, Alberto Ocana
Oncotarget|January 22, 2017
Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studiesAlberto Ocana, Atanasio Pandiella
Journal of the National Cancer Institute|December 7, 2010
When are "positive" clinical trials in oncology truly positive?Alberto Ocana, Ian F Tannock
Breast (Edinburgh, Scotland)|June 27, 2015
One step forward, two steps back: The story of everolimus in advanced breast cancerSaroj Niraula, Alberto Ocana, Eitan Amir
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2011
Clinical research: show us the dataAlberto Ocana, Eitan Amir, Bostjan Seruga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Multidimensional challenges in clinical drug development, regulatory approval, and marketingAlberto Ocana, Bostjan Seruga, Eitan Amir
Lancet (London, England)|February 24, 2015
Pathological complete response in breast cancerAlberto Ocana, Bostjan Seruga, Eitan Amir
Cancer Research|May 20, 2016
Toward Value-Based Pricing to Boost Cancer Research and InnovationAlberto Ocana, Eitan Amir, Ian F Tannock
Nature Reviews. Clinical Oncology|September 23, 2010
Drug resistance in metastatic castration-resistant prostate cancerBostjan Seruga, Alberto Ocana, Ian F Tannock
Pageof 10